Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34 Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-K Annual Report HTML 1.44M
4: EX-10.27 Material Contract HTML 34K
5: EX-10.28 Material Contract HTML 29K
6: EX-10.31 Material Contract HTML 76K
7: EX-10.34 Material Contract HTML 57K
2: EX-10.6 Material Contract HTML 74K
3: EX-10.8 Material Contract HTML 80K
8: EX-21.1 Subsidiaries List HTML 26K
9: EX-23.1 Consent of Experts or Counsel HTML 28K
10: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 31K
13: EX-32.2 Certification -- §906 - SOA'02 HTML 31K
20: R1 Document and Entity Information HTML 56K
21: R2 Consolidated Balance Sheets HTML 104K
22: R3 Consolidated Balance Sheets (Parenthetical) HTML 55K
23: R4 Consolidated Statements of Operations and HTML 95K
Comprehensive Loss
24: R5 Consolidated Statements of Changes in Convertible HTML 207K
Preferred Stock and of Stockholders? Equity
(Deficit)
25: R6 Consolidated Statements of Changes in Convertible HTML 37K
Preferred Stock and of Stockholders? Equity
(Deficit) (Parenthetical)
26: R7 Consolidated Statements of Cash Flows HTML 194K
27: R8 The Company and Basis of Presentation HTML 47K
28: R9 Summary of Significant Accounting Policies HTML 81K
29: R10 Revenue and License Agreements HTML 36K
30: R11 Medicis Settlement HTML 42K
31: R12 Cash Equivalents and Investments HTML 96K
32: R13 Fair Value Measurements HTML 96K
33: R14 Balance Sheet Components HTML 71K
34: R15 Notes Payable HTML 50K
35: R16 Convertible Notes, Warrants, and Related HTML 44K
Derivatives
36: R17 Interest Expense HTML 61K
37: R18 Commitments and Contingencies HTML 49K
38: R19 Common Stock HTML 46K
39: R20 Convertible Preferred Stock HTML 31K
40: R21 Warrants HTML 37K
41: R22 Net Income (Loss) per Share Attributable to Common HTML 81K
Stockholders
42: R23 Stock Option Plan HTML 288K
43: R24 Income Taxes HTML 94K
44: R25 Defined Contribution Plan HTML 32K
45: R26 Subsequent Events HTML 32K
46: R27 Quarterly Results of Operations (Unaudited) HTML 85K
47: R28 Summary of Significant Accounting Policies HTML 145K
(Policies)
48: R29 Cash Equivalents and Investments (Tables) HTML 94K
49: R30 Fair Value Measurements (Tables) HTML 89K
50: R31 Balance Sheet Components (Tables) HTML 71K
51: R32 Notes Payable (Tables) HTML 33K
52: R33 Interest Expense (Tables) HTML 59K
53: R34 Commitments and Contingencies (Tables) HTML 36K
54: R35 Common Stock (Tables) HTML 44K
55: R36 Net Income (Loss) per Share Attributable to Common HTML 82K
Stockholders (Tables)
56: R37 Stock Option Plan (Tables) HTML 263K
57: R38 Income Taxes (Tables) HTML 83K
58: R39 Quarterly Results of Operations (Unaudited) HTML 84K
(Tables)
59: R40 The Company and Basis of Presentation - Additional HTML 93K
Information (Detail)
60: R41 Summary of Significant Accounting Policies HTML 53K
(Details)
61: R42 Revenue and License Agreements (Details) HTML 53K
62: R43 Medicis Settlement - Additional Information HTML 69K
(Detail)
63: R44 Cash Equivalents and Investments (Details) HTML 51K
64: R45 Cash Equivalents and Investments Remaining HTML 36K
Contractual Maturities Available-for-Sale
Securities (Details)
65: R46 Fair Value Measurements - Schedule of Fair Value HTML 60K
of Financial Instruments (Detail)
66: R47 Fair Value Measurements - Summary of Changes in HTML 35K
Fair Value of Financial Instruments (Detail)
67: R48 Fair Value Measurements (Narrative) (Details) HTML 30K
68: R49 Balance Sheet Components - Additional Information HTML 35K
(Detail)
69: R50 Balance Sheet Components - Schedule of Property HTML 48K
and Equipment, Net (Detail)
70: R51 Balance Sheet Components - Schedule of Prepaid HTML 39K
Expenses and Other Current Assets (Detail)
71: R52 Balance Sheet Components - Schedule of Accruals HTML 48K
and Other Current Liabilities (Detail)
72: R53 Notes Payable - Hercules Notes Payable (Detail) HTML 62K
73: R54 Notes Payable - Essex Capital Notes (Detail) HTML 81K
74: R55 Notes Payable - Summary of Aggregate Total Future HTML 35K
Minimum Lease Payments under the Financing
Obligation (Detail)
75: R56 Convertible Notes, Warrants, and Related HTML 112K
Derivatives - Additional Information (Detail)
76: R57 Interest Expense - Summary of Interest Expense by HTML 49K
Cash and Non-Cash Components (Detail)
77: R58 Commitments and Contingencies - Additional HTML 49K
Information (Detail)
78: R59 Commitments and Contingencies - Schedule of Future HTML 45K
Minimum Lease Payments under Non-Cancelable
Operating Leases (Detail)
79: R60 Common Stock - Additional Information (Detail) HTML 50K
80: R61 Convertible Preferred Stock - Additional HTML 37K
Information (Detail)
81: R62 Warrants - Additional Information (Detail) HTML 98K
82: R63 Net Income (Loss) per Share Attributable to Common HTML 80K
Stockholders - Schedule of Computation of Basic
and Diluted Net Income (Loss) Per Share
Attributable to Common Stockholders (Detail)
83: R64 Net Income (Loss) per Share Attributable to Common HTML 45K
Stockholders - Summary of Common Stock Equivalents
Excluded from Computation of Diluted Net Income
(Loss) Per Share (Detail)
84: R65 Stock Option Plan - Additional Information HTML 127K
(Detail)
85: R66 Stock Option Plan - Summary of Stock Option and HTML 146K
Restricted Stock Award Activity (Details)
86: R67 Stock Option Plan - Stock Options Outstanding and HTML 78K
Exercisable (Details)
87: R68 Stock Option Plan - Summary of Restricted Stock HTML 58K
Award Activity (Details)
88: R69 Stock Option Plan - Fair Value Assumptions HTML 48K
(Details)
89: R70 Stock Option Plan - Schedule of Stock-based HTML 37K
Compensation Expense (Details)
90: R71 Income Taxes - Additional Information (Detail) HTML 61K
91: R72 Income Taxes - Deferred Tax Assets and Liabilities HTML 54K
(Details)
92: R73 Income Taxes - Effective Tax Rate Reconciliation HTML 50K
(Details)
93: R74 Income Taxes - Unrecognized Tax Benefits (Details) HTML 38K
94: R75 Defined Contribution Plan - Additional Information HTML 29K
(Details)
95: R76 Subsequent Events - Additional Information HTML 51K
(Details)
96: R77 Quarterly Results of Operations (Unaudited) - HTML 52K
Additional Information (Details)
98: XML IDEA XML File -- Filing Summary XML 169K
97: EXCEL IDEA Workbook of Financial Reports XLSX 112K
14: EX-101.INS XBRL Instance -- rvnc-20151231 XML 3.05M
16: EX-101.CAL XBRL Calculations -- rvnc-20151231_cal XML 259K
17: EX-101.DEF XBRL Definitions -- rvnc-20151231_def XML 757K
18: EX-101.LAB XBRL Labels -- rvnc-20151231_lab XML 2.19M
19: EX-101.PRE XBRL Presentations -- rvnc-20151231_pre XML 1.23M
15: EX-101.SCH XBRL Schema -- rvnc-20151231 XSD 225K
99: ZIP XBRL Zipped Folder -- 0001479290-16-000031-xbrl Zip 302K
1. I have reviewed this annual report on Form 10-K of Revance Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of
the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
